Key Stats for Eli Lilly Stock
- 52-Week Range: $623.78 – $1,182.73
- Current Price: $1,122.50
- Street Mean Target: $1,215.79
- TIKR Model Target (Mid Case): $2,977.65
- Annualized IRR: ~15%
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What’s Driving the Rally
Eli Lilly (LLY) has spent the past month adding to a list of catalysts that would normally be spread across an entire year. Strong Phase 3 data on retatrutide, the company’s next-generation obesity candidate, pushed the stock to a fresh 52-week high in early June.
That data matters because retatrutide is showing a greater weight-loss effect than Zepbound, and it landed just as Novo Nordisk’s own next-generation candidate, CagriSema, missed its primary endpoint in a head-to-head trial. The gap between the two companies, already wide, got wider.
None of this happened in a vacuum. Q1 revenue grew 56% to $19.8 billion, with non-GAAP EPS up 156% to $8.55. Mounjaro revenue rose 125% to $8.7 billion, and Zepbound revenue rose 80% to $4.1 billion.
Lilly raised full-year revenue guidance to a range of $82 billion to $85 billion on the back of that strength. The revenue chart shows just how recently this acceleration started. Annual revenue sat in the high $20 billion range for two straight years before more than doubling over two fiscal years.
See historical and forward estimates for Eli Lilly stock (It’s free!) >>>
The Pipeline Is Doing the Heavy Lifting
The most important regulatory event of the quarter was the FDA approval of Foundayo, Lilly’s oral GLP-1 pill. Foundayo is the first GLP-1 in pill form that patients can take at any time of day without food or water restrictions, removing one of the biggest barriers to adoption in the entire category.
Management has been clear that this is meant to expand the total pool of patients willing to start treatment, not just shift existing injectable patients to a pill.
Retatrutide is the bigger long-term story. It works as a triple agonist, meaning it targets three separate metabolic pathways rather than the one or two that current GLP-1 drugs target, and early data suggest this translates into materially better outcomes.
Lilly also continued to add to its pipeline through acquisitions, including a deal for 4E Therapeutics that brings in a non-opioid pain candidate with a mechanism distinct from existing chronic pain treatments. None of that shows up in current revenue, which is exactly the point bulls are making.
The growth investors are paying for today is mostly still ahead of the company.
See how Eli Lilly performs against its peers in TIKR (It’s free!) >>>
What the Valuation Model Says
At $1,122.50, Lilly trades at roughly 30 times forward earnings, a premium that has to be justified by sustained double-digit growth for years to come. TIKR’s model puts the mid-case target at $2,977.65 by the end of 2030, implying a total return of around 88% and an annualized return near 15%.
That case assumes revenue growth slows to around 12% annually, with net income margins expanding from current levels toward the low 40% range as the obesity franchise scales.
The risk to that path is pricing, not demand. Lower realized prices on Mounjaro and Zepbound already shaved meaningful percentage points off revenue growth this quarter, and that pressure compounds as employers reconsider GLP-1 coverage heading into 2027.
The bear case isn’t that people stop wanting these drugs. It’s that Lilly ends up selling more of them for less, which is a very different margin outcome than the current stock price assumes.
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free!) >>>
Should You Invest in Eli Lilly
Lilly’s combination of in-market growth and pipeline depth is rare for a company this size. Retatrutide alone could extend the company’s lead in obesity by years, and Foundayo opens the door to patients who would never have started an injectable.
The risk is that almost all of this is already reflected in a stock trading near all-time highs, which leaves little room for anything short of clean execution.
The Street’s mean target of $1,215.79 implies modest near-term upside from here, while TIKR’s model sees a credible path to meaningfully higher long-term returns if the obesity franchise scales as management expects.
The 2027 pricing and coverage questions are real, but they are the kind of risk that shows up gradually rather than all at once, giving investors time to watch how it plays out before deciding how much conviction the position deserves.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
